Structure and Function of Integrase

Integrase的结构和功能

• 批准号: 8463943
• 负责人: ANNA MARIE SKALKA
• 金额: $ 41.95万
• 依托单位: RESEARCH INST OF FOX CHASE CAN CTR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8463943
• 关键词: AIDS therapy; AIDS/HIV problem; Active Sites; Address; Affect; Amino Acid Substitution; Architecture; Avian Sarcoma Viruses; Binding; Biological Assay; Catalysis; Chemicals; Clinical; Clinical Trials; Complement; Coupled; DNA; DNA Binding; Data; Data Analyses; Deuterium; Development; Drug Targeting; Enzymes; FDA approved; Fluorescence; Funding; HIV; HIV Integrase; HIV drug resistance; HIV-1; Hydrogen; Integrase; Integrase Inhibitors; Knowledge; Lead; Length; Maps; Mass Spectrum Analysis; Measures; Methods; Modeling; Molecular Conformation; Monitor; Pharmaceutical Preparations; Positioning Attribute; Property; Proteins; Publishing; Reaction; Research; Roentgen Rays; Role; Shapes; Site; Solutions; Spumavirus; Structural Models; Structure; Testing; Therapeutic; Viral; Viral Physiology; Virus; base; crosslink; design; dimer; drug development; in vitro activity; inhibitor/antagonist; insight; monomer; mutant; novel strategies; novel therapeutics; physical model; prototype; research study; screening; single-molecule FRET; small molecule libraries; success; viral DNA; viral resistance

DESCRIPTION (provided by applicant): Integrase (IN) is one of three virus-encoded enzymes that are essential for retroviral replication and a validated target for the development of drugs t treat HIV/AIDS. Although there has been success in developing clinically useful drugs that block the final step in the integration reaction, the so-called strand transfer inhibitors, there is a continuing need to augment or replace existing IN therapeutics as viral resistance is encountered. A detailed knowledge of all aspects of the structure, assembly, and catalysis by HIV-1 IN, will reveal unexploited vulnerabilities and novel strategies for inhibiting this critical enzyme. In the current funding period, we applied small angle X-ray scattering (SAXS) and protein-protein cross-linking methods to obtain the first experimentally-derived models of full-length unliganded apo-IN monomers and dimers in solution, using avian sarcoma virus (ASV) IN. The results revealed a dimer architecture (called a reaching dimer) that was previously unsuspected. The configuration of the reaching dimer resembles that of the viral DNA-binding, "inner" dimer in the crystal structure of the prototype foamy virus (PFV) IN. From these and other data, we have constructed a structural model for an HIV IN reaching dimer, which we hypothesize is pre-positioned to interact with viral DNA ends. In Aim 1 of this competitive renewal we propose to test this model by determining the solution structures of monomers, dimers, and tetramers of HIV IN, using methods successfully employed with ASV IN. We will identify the interactions that stabilize HIV dimers and determine the effects of substrate binding on their conformation. In Aim 2 we will identify compounds that alter the stability of HIV apo-IN dimers and inhibit the conformational changes that are required for IN function. The results of our studies will provide critical new information concerning HIV IN structure and function, and contribute to the design of new, allosterically-acting drugs that can complement the active site inhibitors now in clinical use.

描述（由申请人提供）：整合酶（IN）是逆转录病毒复制所必需的三种病毒编码酶之一，是开发治疗HIV/AIDS药物的有效靶点。尽管已经成功地开发了阻断整合反应中的最后一步的临床上有用的药物，即所谓的链转移抑制剂，但是随着遇到病毒抗性，仍然需要增加或替换现有的IN治疗剂。详细了解HIV-1 IN的结构、组装和催化的各个方面，将揭示尚未利用的漏洞和抑制这种关键的免疫反应的新策略。 酵素在当前的资助期内，我们应用小角X射线散射（SAXS）和蛋白质-蛋白质交联方法，使用禽肉瘤病毒（ASV）IN，获得了第一个实验衍生的全长无配体载脂蛋白IN单体和二聚体的模型。结果揭示了一个二聚体结构（称为到达二聚体），这是以前未被怀疑。到达二聚体的构型类似于原型泡沫病毒（PFV）IN的晶体结构中的病毒DNA结合“内部”二聚体的构型。从这些和其他数据，我们已经构建了一个结构模型的HIV IN达到二聚体，我们假设是预先定位与病毒DNA末端相互作用。在目标1的竞争性更新，我们建议测试这个模型，通过确定解决方案的结构的单体，二聚体，和四聚体的HIV IN，使用的方法成功地与ASV IN。我们将确定稳定HIV二聚体的相互作用，并确定底物结合对其构象的影响。在目标2中，我们将鉴定改变HIV apo-IN二聚体的稳定性并抑制IN功能所需的构象变化的化合物。我们的研究结果将提供有关HIV IN结构和功能的重要新信息，并有助于设计新的变构作用药物，以补充目前临床使用的活性位点抑制剂。